Better biomarkers to detect smoking are needed given the tremendous public health burden caused by smoking. Current biomarkers to detect smoking have significant limitations, notably a short half-life for detection and lack of sensitivity for light smokers. These limitations may be particularly problematic in populations with less accurate self-reporting. Prior epigenome-wide association studies indicate that methylation status at cg05575921, a CpG residue located in the aryl hydrocarbon receptor repressor (AHRR) gene, may be a robust indicator of smoking status in individuals with as little as half of a pack-year of smoking. In this study, we show that a novel droplet digital PCR assay for measuring methylation at cg05575921 can reliably detect smoking status, as confirmed by serum cotinine, in populations with different demographic characteristics, smoking histories, and rates of false-negative self-report of smoking behavior. Using logistic regression models, we show that obtaining maximum accuracy in predicting smoking status depends on appropriately weighting self-report and cg05575921 methylation according to the characteristics of the sample being tested. Furthermore, models using only cg05575921 methylation to predict smoking perform nearly as well as those also including self-report across populations.
with regular smoking (Shadel, Shiffman, Niaura, Nichter, & Abrams, 2000) . In smokers who are already nicotine dependent, detection of current smoking status can allow clinicians to refer those individuals for smoking cessation treatments (Ranney, Melvin, Lux, McClain, & Lohr, 2006) . Lastly, detection of smoking status is important in monitoring for relapse after smoking cessation treatment has been completed (Jatlow, Toll, Leary, Krishnan-Sarin, & O'Malley, 2008; McClure, 2001 ).
In current clinical practice, assessment of smoking is usually limited to self-report (Larzelere & Williams, 2012) . While self-report has been shown to be generally accurate in adults in epidemiologic studies (Caraballo, Giovino, Pechacek, & Mowery, 2001; Vartiainen, Seppala, Lillsunde, & Puska, 2002) , there are important exceptions in some populations. For example, pregnant women (Britton, Brinthaupt, Stehle, & James, 2004) , adolescents (Caraballo, Giovino, & Pechacek, 2004; Kandel et al., 2006) , and African-Americans (Wagenknecht, Burke, Perkins, Haley, & Friedman, 1992) have all been reported to have elevated rates of disagreement between self-report of smoking behavior and objective measures of recent smoking, such as cotinine concentration. In addition, unreliable self-report is a well-established phenomenon in nicotine dependence treatment populations (Hilberink et al., 2011; Philibert et al., 2016 ).
Cotinine, the major metabolite of nicotine, is typically measured in body fluids such as saliva, urine, or serum by enzyme-linked immunoassay (ELISA) (Benowitz, Hukkanen, & Jacob, III, 2009 ).
Although cotinine is commonly cited as the gold standard biomarker for smoking detection, it has significant limitations, most notably a short half-life of approximately 20 hr (Benowitz, Bernert, Caraballo, Holiday, & Wang, 2009 ). Determination of current smoking status by cotinine assay can also result in false-positives in individuals who have quit smoking but are using nicotine replacement therapies, which limits its usefulness in populations being treated for nicotine dependence (Benowitz, Hukkanen, et al., 2009; Florescu et al., 2009; Jatlow et al., 2008; Matsumoto et al., 2010) . Exhaled carbon monoxide (CO), an alternative biomarker for smoking, has an even shorter half-life of 4-5 hr and requires specialized equipment at the point of testing (Florescu et al., 2009) . Importantly, neither cotinine nor CO offer adequate sensitivity in the detection of the light or intermittent smoking patterns that characterize adolescent use, a time when preventative interventions may be able to interrupt progression to nicotine dependence (Flay, 2009 ).
Epigenetic biomarkers have the potential to overcome many of the limitations of current biomarkers in detecting smoking. Epigenetic marks are mitotically heritable modifications to DNA that provide structural and regulatory functions for the genome without the presence of a change in base pair sequence (Goldberg, Allis, & Bernstein, 2007) . These marks include methylation of the cytosine base at cytosine-phospho-guanine dinucleotide residues (CpGs), covalent modification of histones, and open versus closed chromatin states, all of which can affect the expression of genes (Jiang, Bressler, & Beaudet, 2004) . Critically, some epigenetic marks are responsive to environmental influences, such as tobacco smoke exposure (Bollati & Baccarelli, 2010; Ladd-Acosta, 2015) . The development of array-based platforms such as Illumina's Infinium HumanMethylation450 BeadChip system has allowed investigators to perform epigenome-wide association studies to uncover links between environmental exposures and epigenetic changes. As a result of these investigations, tobacco smoke has emerged as a paradigmatic environmental exposure with epigenetic effects (Mikeska & Craig, 2014) .
In particular, one locus, cg05575921, a CpG residue located in the gene for the aryl hydrocarbon receptor repressor (AHRR), is a leading candidate for translation as a clinical biomarker for smoking (Ladd-Acosta, 2015; Mikeska & Craig, 2014) . In over 30 methylomewide studies of smoking conducted to date using self-report and cotinine validation of smoking status, across a wide variety of age ranges, ethnicities, both sexes, and even in infants exposed prenatally, demethylation of cg05575921 has been consistently linked with tobacco smoke exposure (Andersen, Dogan, Beach, & Philibert, 2015) .
Studies by Fasanelli and Baglietto and coworkers have further demonstrated that demethylation of cg05575921 is an independent risk factor for lung cancer after adjusting for smoking status (Baglietto, Ponzi, Haycock, Hodge, & Campanella, 2017; Fasanelli et al., 2015) .
The mechanism underlying this consistent epigenetic response to smoking is not fully understood, but is thought to involve activation of the xenobiotic pathway. The xenobiotic pathway, responsible for detoxifying harmful components of tobacco smoke including polyaromatic hydrocarbons and dioxins (Nguyen & Bradfield, 2008) , is induced by the binding of polyaromatic hydrocarbons to the aryl hydrocarbon receptor (AHR). Subsequently, AHRR expression increases to compete with AHR for binding to its nuclear receptor, preventing over-expression of downstream genes such as p450 enzymes that detoxify components of smoke. Increased AHRR expression is directly linked to demethylation at CpG sites in the AHRR gene, including cg05575921, and measurement of this change in methylation then serves as a robust indicator of both smoking and other exposures that upregulate the xenobiotic pathway .
The performance characteristics of cg05575921 in detecting smoking are excellent, with an AUC of 0.99 reported in one study which used serum cotinine to confirm smoking status . This excellent predictive ability appears to be driven by two key factors. First, cg05575921 appears to have a fairly narrow biological "set-point," with non-smokers almost always having a value of 80-90% methylation. Second, the magnitude of the change in percent methylation or "delta beta" in this locus in response to smoking is large compared to other smoking-associated loci . While delta beta values for methylation biomarkers in noncommunicable diseases are typically less than 5% (Mikeska & Craig, 2014) , multiple studies have reported a delta beta of 15-20% at cg05575921 in response to smoking (Dogan et al., 2014; Elliott et al., 2014; Tsaprouni et al., 2014; Zeilinger et al., 2013) . A recent metaanalysis of epigenetic signatures of smoking by Joehanes et al. (2016) reported a delta beta of 18% for cg05575921, the largest of 2623
CpGs associated with smoking, although it ranked only 36th in statistical significance whereas a 2015 review of 14 epigenome wide studies by Brenner and coworkers showed that cg05575921 had both the largest delta beta and the smallest p-value in the epigenome (Gao, Jia, Zhang, Breitling, & Brenner, 2015) .
A third critical factor is that this locus is responsive even to light or intermittent smoking. In one study of 19-year-old smokers versus controls, smokers with less than 1/2 pack-year smoking history had a measurable delta beta at cg05575921 of 4.9% (Philibert, Beach, & Brody, 2012) .
The extent of reversion of demethylation of cg05575921 with smoking cessation is uncertain and in need of further study. Several studies show demethylation at this locus in subjects who reported quitting smoking decades earlier (Baglietto et al., 2017; Fasanelli et al., 2015; Guida et al., 2015; Shenker et al., 2013) . However, using biochemically confirmed measures, we have shown average reversion of nearly 5% after 1 month of cessation whereas Bauer and coworkers show complete erasure of the demethylation response present in the cord blood in offspring of smoking mothers after only 2 years.
While the epigenome-wide studies cited above used chip-based assays for discovery, the cost of arrays and their long turnaround time Digital PCR methylation assays require genomic DNA that has been treated with bisulfite, a process that converts unmethylated cytosines to uracils, while sparing methylated cytosines (Frommer et al., 1992) . Bisulfite-converted DNA is then amplified using primers specific for both the methylated and unmethylated alleles. The relative abundance of each allele is then measured, allowing for calculation of the relative abundance of methylated and unmethylated alleles in the original sample. Digital PCR methods differ from quantitative PCR (qPCR) techniques by allowing highly precise quantification of the original sample without an external reference (Hindson et al., 2011) . This is accomplished by fractionating the sample into a large number of separate PCR reactions, typically 15,000-20,000. The fractional abundance of each allele in the original sample is calculated based on the number of positive and negative reactions, assuming a Poisson distribution. One application of this method is to use hydrophobic droplets to encapsulate and fractionate the samples, a technique known as droplet digital PCR (ddPCR) (Hindson et al., 2011) . In one study, measurement of methylation at a promoter CpG in the CD3Z gene was used to estimate T cell numbers in peripheral blood using both ddPCR and qPCR, and ddPCR was reported to offer superior precision, accuracy, and technical simplicity (Wiencke et al., 2014) .
For the detection of smoking, a clear application of methylationspecific ddPCR assays is the measurement of cg05575921 methylation in an individual in order to determine if it is lower than the population "set-point" of 80-90%. Values progressively lower than this population average signal an increasing probability that the person is a smoker. Indeed, Zhang, Florath, Saum, and Brenner (2016) have demonstrated a strong linear relationship between progressive demethylation of cg05575921 and both cotinine and the number of cigarettes smoked per day.
In clinical practice, however, this information must also be integrated with self-report data and knowledge of the smoking habits characteristic of the individual's population, given that neither laboratory testing nor self-report have perfect sensitivity or specificity.
Thus when integrating information from an epigenetic biomarker such as cg05575921 with self-report, it is important to develop models that weight each source of information appropriately to guide clinical decision in different populations.
Here, we employ ddPCR to compare methylation at cg05575921 in two cotinine-validated samples of current smokers versus nonsmokers with differing rates of false-negative self-reporting and cumulative smoking histories. We show that cg05575921 is a robust predictor of cotinine positivity in both samples. We further show that logistic models trained in different samples vary in predictive accuracy depending on the level of false negative self-reporting of smoking status in both training and test samples.
| MATERIALS AND METHODS

| Samples
The Iowa Adoption Studies (IAS) is a long-running study of adoptees from the State of Iowa whose focus is substance use disorders and related psychopathology. The methods used in this study have been described previously (Philibert, 2006) . Briefly, 475 adoptees with a biological family history of substance use or antisocial personality disorder were selected from among 11,700 adoptees statewide, along with a matched sample of 475 controls. These adoptees and their families then were followed over 30 years with repeated assessments including semi-structured interviews including a modified version of the Semi Structured Assessment for the Genetics of Alcoholism, Version 2 (SSAGA-II) (Bucholz et al., 1994) (Kogan et al., 2013; Simons, Simons, Lei, & Landor, 2012) . Of particular relevance, each family who participated in the FACHS study included at least one child between the ages of 10 and 12 years old at the time of recruitment (1995) (1996) (1997) . During the last wave of the study, wave seven (2014) (2015) (2016) , each subject was interviewed by a trained research assistant using a customdesigned structured interview, then phlebotomized to provide materials for the current study. The structured interview included assessment of subject smoking status and total number of cigarettes smoked in their lifetime. Of note, data to calculate the number of pack-years smoked were not available for this
sample but participants did report on whether they had smoked 500 or more cigarettes in their lifetime.
All procedures and protocols used in the IAS sample were approved by the University of Iowa Institutional Review Board (IRB).
Similarly, all procedures and protocols for the FACHS sample were approved by IRB panels at Iowa State University, University of Iowa, or University of Georgia.
| Biomaterials
Following phlebotomy of the FACHS subjects, whole blood DNA and sera were prepared according to previously published protocols (Philibert et al., 2012; Philibert, Beach, Lei, & Brody, 2013b) . Similarly, for IAS subjects, whole blood DNA was obtained via the same method (Lahiri & Schnabel, 1993) while plasma was obtained via ultrafiltration of blood samples frozen at −80°C.
Cotinine levels were assayed using ELISA with kits supplied by Abnova (Taoyuan City, Taiwan) as previously described (Philibert, Beach, Lei, & Brody, 2013a) . To minimize the effects of unfiltered hemoglobin, washes conducted during processing of the plasma samples were conducted with phosphate-buffered saline, pH 8.0, per the manufacturer's suggestion.
Determination of methylation status at cg05575921 was conducted using ddPCR implementation of the previously described quantitative PCR approach (Dogan et al., 2014) . First, 1 μg of DNA from each subject was bisulfite converted using an EpiTect 
| Statistical analysis
All subsequent analyses were conducted with the R (Team, 2014) statistical software, using the pROC (Robin et al., 2011) and the scoring (Merkle & Steyvers, 2013) packages. Cotinine positivity was coded as 0 for individuals with 3 ng/ml or less and 1 for those above 3 ng/ml (Benowitz, Bernert, et al., 2009) . Positive self-report of smoking was coded as a 1 and negative self-report as a 0. Subjects failing quality control, defined as greater than a 5% confidence interval for the ddPCR assay, were excluded from further analysis (N = 31 in IAS and N = 17 in FACHS).
For the primary analysis, logistic models were fit for each sample using cotinine positivity as the outcome and, cg05575921 methylation only (model 1), self-report only (model 2), and both self-report and cg05575921 methylation (model 3) as predictors. An intercept-only model (model 0) was also fit with no predictors. For between-sample predictions the full IAS or FACHS sample was used for training and subsequent testing. For within-sample model fitting and prediction, 70-30% random splits within each sample were made using the R package caret (Kuhn, 2015) . Each model was then trained on the 70% split and cotinine status predicted in the corresponding 30% split within each sample.
Regression coefficients were estimated via maximum likelihood methods and Akaike's information criterion (AIC) was used to assess relative model fit in each of the models above. Each of the four logistic models trained in each sample were then used to predict the probability of cotinine positivity within and across samples, using the full or split samples for training and testing as applicable.
Predicted probabilities were used to construct receiver operating characteristic curves (Zou, O'Malley, & Mauri, 2007) and calculate the area under the curve (AUC) with 95% confidence interval for each set of predictions. The Brier score (Redelmeier, Bloch, & Hickam, 1991 (Gerds, Cai, & Schumacher, 2008; Steyerberg et al., 2010) . Brier scores for each set of predictions were calculated as the sum of squared distance between a participant's smoking status as classified by cotinine and their predicted status based on the estimated regression coefficients (i.e., based on the linear predictor). Scaled Brier scores were then calculated to estimate the corresponding R 2 for each set of predictions.
We performed an additional adjusted analysis of model 3 in the IAS sample to examine the effect of including pack-years and age as predictors of cg05575921 methylation and cotinine positivity. First, a linear model was fit using cg05575921 methylation as the outcome and age, pack-years, self-report and cotinine positivity as predictors, and p-values for each parameter were inspected. Next, we included age and pack-years as additional predictors in our full logistic model (model 3) in the IAS 70% training split. Predictions from this adjusted model were then made in the IAS 30% testing split and used to calculate an AUC and Brier score using the same methods as above.
The function roc.test() in the pROC package was then used to compare the resulting AUC with that of the unadjusted model.
A secondary analysis was performed to examine differences in the regression coefficients among between samples. The goal was to test the null hypothesis of equal population regression coefficients for selfreport and cg05575921 among the population counterparts of the FACHS and IAS samples. Additional logistic regression models were estimated using the combined data with a dummy code for sample membership (FACHS = 0, IAS = 1), which was included as another predictor. The interaction of the dummy code and self-report, and the dummy code and cg05575921 was included in the full model (model 4) in order to test for invariance of the regression coefficients among FACHS and IAS. We refer to this secondary analysis as the sampleas-group analysis.
| RESULTS
Clinical characteristics of the two samples are given in Table 1 . In brief, the IAS sample (n = 209) was older, predominantly EuropeanAmerican, and had reported greater cumulative smoke exposure, with a mean lifetime consumption of 17.9 pack years among the selfreported current smokers. In contrast, subjects in FACHS (n = 592)
were younger, almost entirely African-American, more likely to be female, and had significantly less self-reported smoking. Although data to calculate self-reported pack-years were not available for the FACHS subjects, only 15.2% of FACHS subjects reported having smoked more than 500 cigarettes (roughly 0.07 pack-years) or more in their lifetime.
Comparison of self-reported current smoking status with biochemical evidence of current smoking via serum cotinine revealed distinct patterns across the two samples, as shown in Table 2 . Selfreported rates of smoking in IAS and FACHS were 26.8% and 31.8%, respectively, while serum cotinine positivity was seen in 33.5% of IAS subjects and 51.7% of FACHS subjects. Among IAS subjects, the proportion denying current smoking but positive for serum cotinine was 7%, while in FACHS the corresponding proportion was 22.6%.
Only one (0.5%) of the IAS subjects self-reported current smoking but was not positive for serum cotinine, while 16 (2.7%) in FACHS did, and the remainder in each sample were negative for cotinine as well as selfreport.
Mean methylation values at cg05575921 for the sample groups, broken down by self-report of current smoking and serum cotinine positivity, are also given in Table 2 Results of the primary analysis are shown in Table 3 In adjusted analyses in the IAS sample, self-report and cotinine positivity were both significant predictors (p < 0.001) of cg05575921 methylation, while pack-years was an even more 
| DISCUSSION
In this study, we show that cg05575921 methylation status is an excellent predictor of current smoking status, as ascertained by serum cotinine, in two samples with very different demographics, smoking histories, and rates of false self-reporting of smoking behavior. Outof-sample prediction was similar to in-sample prediction illustrating that cg05575921 methylation is robust to differences in sample characteristics.
This ddPCR assay is a different measurement approach than used in prior studies investigating epigenetic signatures of smoking, the majority of which used the Illumina Infinium HumanMethylation450
BeadChip array and found methylation at cg05575921 in cotinine confirmed non-smokers to be between 86% and 93% . In the current study, the range for non-smokers was largely between 80% and 88%. Although each of these approaches have their biases (Olson et al., 2016; Soto, Rodriguez-Antolin, Vallespin, de Castro Carpeno, & Ibanez de Caceres, 2016) and the results between the assays are highly correlated (Dogan et al., 2014) , we note that the normal range observed herein is very similar to that obtained by Novakovic et al. (2014) who used a mass spectroscopy approach.
Therefore, when comparing results obtained from the two platforms, it is important to keep in mind that while both of these techniques appear quite reliable, subtle differences between studies may arise from both sample and assay characteristics.
We focused our analyses on two complementary measures of model performance to assess the relative contributions of cg05575921 methylation and self-report in predicting current smoking status: the AUC and the Brier score. Despite some limitations, the calculation of overall AUCs remains the de facto method of comparing classifiers such as biomarkers (Zou et al., 2007) . The AUC values associated with cg05575921 in our study constitute a "good" to "excellent" level of prediction. The effect was consistent in withinsample and across-sample testing, and consistent with prior reports ( | 647 (Zhang et al., 2016) . Self-report performed equally well or better than cg05575921 methylation in testing in the IAS sample, whereas in FACHS the AUC of self-report would be only be classified as "fair." The combination of self-report and cg05575921 methylation provided improved model fit and the best AUC in each train-test combination, although the magnitude of improvement over cg05575921 alone was modest.
Although the consistently high AUC values for cg05575921 methylation seen in this study help validate it as an epigenetic biomarker for current smoking status, this same consistency also highlights a known limitation of the AUC as a measure of model performance. Specifically, models with very similar AUCs may be associated with predictions with large differences in accuracy (Steyerberg et al., 2010) . For a biological relationship such as the one seen in the current study, a monotonic decrease in methylation at cg05575921 with increasing exposure to smoke, logistic models with very different parameter estimates may produce identical or nearly identical rankings of smoking probability. Meanwhile, the actual predictions derived from those parameter estimates may vary widely in terms of accuracy. This weakness was addressed by including the Brier score as an additional validation index in our analysis.
Unlike the AUC, a rank-based non-parametric method, the Brier scores reported in our study are indicators of absolute differences in the accuracy of predictions based on self-report and/or cg05575921 methylation. Once again, a high degree of consistency was seen in within-sample and between-sample testing, with scaled Brier scores As shown by our secondary, samples-as-groups analysis, this effect was driven by the large differences in the accuracy of self-report between our samples, rather than differences in the performance of cg05575921. The difference in regression coefficients between samples for cg05575921 methylation alone was not significant. In contrast, there was a significant difference in the regression coefficient for cg05575921 in the full model that including both cg05575921 and self-report.
Smoking history and age may both influence the accuracy of cg05575921 methylation in predicting current smoking status. In addition, there may be subtle age-related changes in cg05575921 methylation due to unmeasured environmental exposures or intrinsic biological processes. Therefore, we performed additional analyses to assess the impact of age and smoking history on cg05575921 and selfreport as predictors of current smoking status. Because pack-year smoking history data were not available in our FACHS sample, these analyses were restricted to IAS.
As shown above, a logistic model relating cg05575921 methylation to age, pack-years, cotinine positivity, and self-report of current smoking showed significant effects for each predictor except for age.
Further modeling did not support any improvement in predictive utility or accuracy with the inclusion of age and pack-years as predictors, as measured by AUC and Brier scores, respectively. Although these results suggest that cg05575921 alone is a robust predictor of current smoking status even in populations of varying ages and cumulative smoking histories, some limitations of this analysis are notable. First, data were not able to allow us to examine the effect of time since quitting on cg0557521 methylation as a predictor of current smoking.
Additionally, these analyses were restricted to the smaller of our two samples, as cumulative smoking exposure data in FACHS was limited to self-report of having smoked 500 or more cigarettes.
The lack of additional predictive utility or accuracy when including age and pack-years as predictors of current smoking is a surprising finding. Incomplete reversion of cg05575921 methylation after prolonged smoking cessation has been reported in prior work and would be expected to influence prediction of current smoking status (Baglietto et al., 2017; Fasanelli et al., 2015; Guida et al., 2015; Shenker et al., 2013) . One potential explanation of this finding is diminished recall. Diminished recall is a well-established phenomenon in other forms of psychopathology including other forms of substance use (Giuffra & Risch, 1994) . 
